Breast Cancer

Ibrance has received approval from the European Commission to treat metastatic breast cancer.

A 2-year study will examine the effectiveness of advanced MRI to determine response to breast cancer treatment.

Rehabilitation with the help of the internet ameliorates life quality and side effects in women with breast cancer.

Having multiple sclerosis may not increase the risk of breast cancer in women.

Ribociclib seeks approval as a first-line treatment of postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.

The FDA has accepted Novartis’ New Drug Application (NDA) and granted Priority Review for LEE011 (ribociclib).

Stay up-to-date with the hottest news in pharmacy!

Newly-discovered compound blocks an essential protein in sustaining tumor growth.

Ribociclib treats patients with HR+/HER2- advanced or metastatic breast cancer.

Experimental drug treats patients with HR+/HER2- advanced or metastatic breast cancer.

A method to detect underwater structure damage could be used to detect breast cancer.

Only 58% of breast cancer survivors received follow-up mammograms in 2007.

Study challenges previous findings that suggest night shift work increases the risk of breast cancer.

Inhibiting Ran-GTP was associated with reversing and preventing treatment-resistant cancers.

Premenopausal, overweight women have a decreased risk of breast cancer, while postmenopausal women have an increased risk.

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.

LEE011 plus letrozole may prove to be effective first-line breast cancer therapy.

LEE011 plus letrozole demonstrates significant progression free survival in patients with breast cancer.

Device shows promise preventing cancer cells from migrating to other organs in the body.

Using precision medicine, researchers were able to slow down the amount of time it takes for a tumor to grow back in patients with advanced cancer.

Tumor cells grown in mice first could potentially change the cancer research landscape.

Environmental exposure to common chemicals found to inhibit tamoxifen efficacy in breast cancer patients.

Stiffness and hypoxia environments triggers the spread of breast cancer.

Pevonedistat, currently being tested in clinical trials, shows promise in killing melanomas and other cancer types.